Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Lantheus Holdings, Inc.
  6. News
  7. Summary
    LNTH   US5165441032

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
56.20 USD   +0.64%
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH TrialEnrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial
AQ
01/12POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

JonesTrading Starts Lantheus Holdings at Buy With $104 Price Target

10/07/2022 | 05:36am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about LANTHEUS HOLDINGS, INC.
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH TrialEnrollment for..
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial
AQ
01/12POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
AQ
01/11Lantheus Holdings Seeks M&A
CI
01/11Transcript : Lantheus Holdings, Inc. Presents at 41st Annual J.P. Morgan Heal..
CI
01/11Lantheus Holdings, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
01/04Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
GL
2022Lantheus Holdings, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,..
AQ
2022Point Biopharma, Lantheus Close Licensing Deals for Cancer Treatment Candidates
MT
2022Lantheus Holdings, Inc. : Completion of Acquisition or Disposition of Assets, Other Events..
AQ
More news
Analyst Recommendations on LANTHEUS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 917 M - -
Net income 2022 200 M - -
Net Debt 2022 - - -
P/E ratio 2022 19,9x
Yield 2022 -
Capitalization 3 793 M 3 793 M -
Capi. / Sales 2022 4,14x
Capi. / Sales 2023 3,65x
Nbr of Employees 612
Free-Float 97,6%
Chart LANTHEUS HOLDINGS, INC.
Duration : Period :
Lantheus Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANTHEUS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 56,20 $
Average target price 100,33 $
Spread / Average Target 78,5%
EPS Revisions
Managers and Directors
Mary Anne Heino Chief Commercial Officer
Robert J. Marshall Chief Financial Officer & Treasurer
Brian A. Markison Director
Simon Robinson Senior VP-Research & Pharmaceutical Development
Bela S. Denes Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
LANTHEUS HOLDINGS, INC.10.28%3 793
BIOMÉRIEUX-2.80%12 231
DIASORIN S.P.A.-4.56%7 212
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.11.49%6 478
AUTOBIO DIAGNOSTICS CO., LTD.5.80%5 656
10X GENOMICS, INC.33.51%5 569